Executive Chair Eric So Discloses 5.8% Stake After $1.12M Open-Market Buy
HELP has more than doubled off its 52-week low of $3.76.
Summary
Executive Chairman Eric So disclosed a 5.8% beneficial ownership stake in Cybin after buying $1.12M of stock on the open market and receiving a large RSU grant.
Key Events · Ownership and Investor Activity · HELP
-
Executive Chair Buys $1.12M in Stock
Eric So purchased 95,000 common shares at $11.805 per share on September 1, 2026, totaling $1,121,475.
-
Large RSU Grant Awarded
On the same day, So received 1,046,899 restricted stock units, further increasing his equity stake.
-
5.8% Beneficial Ownership Disclosed
So reports aggregate beneficial ownership of 4,423,894 shares (5.8% of class), including 105,264 shares underlying warrants.
-
Insider Accumulation Cluster
This follows a $1.04M open-market purchase by Chief Growth Officer Paul Glavine disclosed earlier today, with 90-day insider net buying at $2.16M.
Analysis · HELP · Life Sciences
Eric So, Cybin's Executive Chairman and co-founder, bought 95,000 shares for $1.12 million at $11.805 per share on September 1, 2026, and was simultaneously awarded 1,046,899 restricted stock units. The purchase is a real cash commitment from a top insider, and the RSU grant further aligns him with shareholders. This comes just days after the company's Chief Growth Officer also made a large open-market purchase, signaling broad insider conviction as the stock trades near its 52-week high.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $13.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $3.76 to $14.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.